Press releaseBusiness Wire
BeOne Medicines AG
ONC · SHANGHAI
$377.63−$4.64 (−1.21%)TodayMarket closed ·
Prev close $382.27
Latest news
- Press releaseBusiness Wire
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
- Press releaseBusiness Wire
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
- News
BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript
- Press releaseBusiness Wire
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
- NewsNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
- Press releaseBusiness Wire
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
- Press releaseBusiness Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
- NewsVandana Singh
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
- Press releaseBusiness Wire
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
- Press releaseBusiness Wire
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
- Press releaseBusiness Wire
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- News
BeiGene Q2 Adj. EPS $3.84 Beats $1.44 Estimate, Sales $1.705B Beat $1.591B Estimate
- Press releaseBusiness Wire
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
- Press releaseBusiness Wire
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
- Press releaseBusiness Wire
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
- NewsVandana Singh
BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy
- Press releaseBusiness Wire
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
- Press releaseBusiness Wire
BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
- Press releaseBusiness Wire
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
- NewsVandana Singh
What's Going On With Summit Therapeutics Stock On Monday?
- Press releaseBusiness Wire
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
- Press releaseBusiness Wire
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
- Press releaseBusiness Wire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
- Press releaseBusiness Wire
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- NewsBamboo Works
BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative
- Press releaseBusiness Wire
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
- Press releaseBusiness Wire
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
- NewsVandana Singh
BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer
- Press releaseBusiness Wire
BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
- News
Earnings Scheduled For May 6, 2026
- News
BeiGene Q1 Adj. EPS $3.24 Beats $0.79 Estimate, Sales $1.513B Beat $1.441B Estimate.
- Press releaseBusiness Wire
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
- Press releaseBusiness Wire
U.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEA
- NewsBamboo Works
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
- NewsAvi Kapoor
C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- News
Earnings Scheduled For February 26, 2026
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.